The article entitled, “Identification of prognosis biomarkers of prostatic cancer in a cohort of 498 patients from TCGA,” by Chen Z and Hu H. (J Comput Biol Dec 2019: e-pub ahead of print; DOI: 10.1089/cmb.2019.0224) is being officially retracted at the authors' request due to errors found in the data after publication of the article. The detected errors render the results and conclusion irreproducible, and therefore, invalid.
Based on the communications received from the authors, the editorial leadership of Journal of Computational Biology agreed to retract the published paper.
However, after retracting the article, it was also discovered that the same article had been previously published in volume 43, issue 6 of the journal, Current Problems in Cancer, published by Elsevier. The publisher of Journal of Computational Biology was in communication with Elseivier since simultaneous submission and/or publication is a violation of the proper protocols of peer review, and they are conducting their own evaluation. Journal of Computational Biology also notified the authors' institution of the infraction.
Journal of Computational Biology
, its Editor, and its Publisher are committed to preserving the integrity of the scientific record for the community it serves.
Get full access to this article
View all access options for this article.
References
1.
BaeJ.M.2015. Human papillomavirus 16 infection as a potential risk factor of prostate cancer: Adaptive meta-analysis. Epidemiol. Health. 37, e2015005.
2.
BandettiniW.P., KellmanP., ManciniC., et al.2012. MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: A clinical validation study. J. Cardiovasc. Magn. Reson., 14, 83.
3.
BertoliG., CavaC., and CastiglioniI.2016. MicroRNAs as biomarkers for diagnosis, prognosis and theranostics in prostate cancer. Int. J. Mol. Sci., 17, 421.
4.
ChangY.S., ChenW.Y., YinJ.J., et al.2015. EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1. Cancer Res. 75, 3077–3086.
5.
CooperbergM.R., BroeringJ.M., LitwinM.S., et al.2004. The contemporary management of prostate cancer in the United States: Lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CAPSURE), a national disease registry. J. Urol. 171, 1393–1401.
6.
DiL., TortoraG., D'ArmientoG., et al.2002. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res. 8, 3438–3444.
7.
FabrisL., CederY., ChinnaiyanA.M., et al.2016. The potential of microRNAs as prostate cancer biomarkers. Eur. Urol. 70, 312–322.
8.
FuY., and WangY.2018. SRSF7 knockdown promotes apoptosis of colon and lung cancer cells. Oncol. Lett. 15, 5545–5552.
9.
GanY., ShiC., IngeL., et al.2010. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene. 29, 4947–4958.
10.
GuinneyJ., WangT., LaajalaT.D., et al.2016. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: Development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol. 18, 132–142.
11.
GuoL.H., LiH., WangF., et al.2013. The tumor suppressor roles of miR-433 and miR-127 in gastric cancer. Int. J. Mol. Sci. 14, 14171–14184.
12.
HanH., HeY., HuJ., et al.2017. Disrupted ER-to-Golgi trafficking underlies anti-HIV drugs and alcohol-induced cellular stress and hepatic injury. Hepatol. Commun. 1, 122.
13.
HarrowJ., FrankishA., GonzalezJ.M., et al.2012. GENCODE: The reference human genome annotation for The ENCODE Project. Genome Res. 22, 1760–1774.
14.
HouW., GuptaS., BeauchampM.C., et al.2017. Non-alcoholic fatty liver disease in mice with heterozygous mutation in TMED2. PLoS One. 12, e0182995.
15.
HwangT.L., LiangY., ChienK.Y., et al.2010. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics. 6, 2259–2272.
16.
KędzierskaH., PopławskiP., HoserG., et al.2016. Decreased expression of SRSF2 splicing factor inhibits apoptotic pathways in renal cancer. Int. J. Mol. Sci., 17, E1598.
17.
KellmanP., ChungY.C., SimonettiO.P., et al.2010. Multi-contrast delayed enhancement provides improved contrast between myocardial infarction and blood pool. J. Magn. Reson. Imaging. 22, 605–613.
18.
KimH.R., LeeG.O., ChoiK.H., et al.2016. SRSF5: A novel marker for small-cell lung cancer and pleural metastatic cancer. Lung Cancer. 99, 57–65.
19.
KohlM., WieseS., and WarscheidB.2011. Cytoscape: Software for visualization and analysis of biological networks. Methods Mol. Biol. 696, 291–303.
20.
KoldeR., and KoldeM.R.2015. Package “pheatmap.” Version.
21.
LeytenG.H., HesselsD., JanninkS.A., et al.2014. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 65, 534–542.
22.
LiJ.Z., WangZ.L., XuW.H., et al.2016. MicroRNA-495 regulates migration and invasion in prostate cancer cells via targeting Akt and mTOR signaling. Cancer Invest. 34, 181–188.
23.
LuoC., ChengY., LiuY., et al.2017. SRSF2 regulates alternative splicing to drive hepatocellular carcinoma development. Cancer Res. 77, 1168–1178.
24.
MaK., LipkowitzS., KlevitR., et al.2014. Abstract 4441: Ube2e inhibits the ubiquitination and degradation of EGFR mediated by Cbl and Ube2d. Cancer Res. 74, 4441.
25.
MaK., RyanP., KlevitR., et al.2016. Abstract 4542: Ube2d family members, Ube2e family members and Ube2w modulate the ubiquitination and degradation of EGFR by Cbl. Cancer Res. 76, 4542.
26.
McfarlaneM., MacdonaldA.I., StevensonA., et al.2015. Human papillomavirus 16 oncoprotein expression is controlled by the cellular splicing factor SRSF2 (SC35). J. Virol. 89, 5276–5287.
27.
MoreiraD.M., HowardL.E., SourbeerK.N., et al.2016. Predicting time from metastasis to overall survival in castration-resistant prostate cancer: Results from SEARCH. Clin. Genitourin. Cancer. 15, 60–66.
28.
NdiayeC., MenaM., AlemanyL., et al.2014. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis. Lancet Oncol. 15, 1319–1331.
29.
NguyenthemL., CostopoulosM., TanguyM.L., et al.2016. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. Eur. J. Cancer. 61, 69–76.
30.
OgawaS., YasuiT., TaguchiK., et al.2014. The probability of involvement of human papillomavirus in the carcinogenesis of bladder small cell carcinoma, prostatic ductal adenocarcinoma, and penile squamous cell carcinoma: A case report. BMC Res. Notes. 7, 909.
31.
RamnarayanV.R., HeinZ., JanßenL., et al.2018. Cytomegalovirus gp40/m152 uses TMED10 as ER anchor to retain MHC class I. Cell Rep. 23, 3068–3077.
32.
SanguedolceF., CormioA., BrunelliM., et al.2016. Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: Literature review. Clin. Genitourin. Cancer. 14, 117–121.
33.
SmythG.K.2005. limma: Linear models for microarray data, 397–420. In GentlemanR., CareyV.J., HuberW., IrizarryR.A., DudoitS., eds. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer, New York.
34.
SteurerS., MayerP.S., AdamM., et al.2014. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. Eur. Urol. 66, 978–981.
35.
SunS., LiangX., ZhangX., et al.2015. Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer. Br. J. Cancer. 112, 1332–1339.
36.
SzklarczykD., MorrisJ.H., CookH., et al.2017. The STRING database in 2017: Quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res. 45, D362–D368.
37.
TherneauT., and LumleyT.2011. Survival: Survival analysis, including penalised likelihood. R package version 2.36-5 and R package version 2.36-2.2010.
38.
WangH., JiangZ., ChenH., et al.2017. MicroRNA-495 inhibits gastric cancer cell migration and invasion possibly via targeting high mobility group AT-Hook 2 (HMGA2). Med. Sci. Monit. 23, 640–648.
39.
WangJ., DuncanD., ShiZ., et al.2013a. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): Update 2013. Nucleic Acids Res. 41, W77–W83.
40.
WangZ., WangY., ZhangJ., et al.2013b. Significance of the TMPRSS2:ERG gene fusion in prostate cancer. BJU Int. 111, 834–835.
41.
YangL., XieS., FengX., et al.2015. Worldwide prevalence of human papillomavirus and relative risk of prostate cancer: A meta-analysis. Sci. Rep., 5, 14667.
42.
YangS., JiaR., and BianZ.2018. SRSF5 functions as a novel oncogenic splicing factor and is upregulated by oncogene SRSF3 in oral squamous cell carcinoma. Biochim. Biophys. Acta– Mol. Cell Res., 1865, 1161–1172.
43.
ZhangJ., LieuY.K., AliA.M., et al.2015. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc. Natl. Acad. Sci. USA. 112, 4726–4734.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
